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The specific bronchial provocative test (sBPT) coupled with allergen is used to investigate asthma. Very few studies
have examined the reproducibility of responses to allergen challenge. The aim of this study was to measure the
reproducibility of PD20FEV1 allergen and late asthmatic response (LAR) in 53 asthmatics and to relate the
reproducibility to the time interval between two allergen challenges.
Fifty-three atopic asthmatics performed two allergen challenges not less than 2 and not more than 26 weeks
apart. Randomly, 19 subjects were assigned to a short-interval group (14–35 days between the two tests) and 34 to a
long-interval group (40–180 days). In each challenge, the PD20FEV1 was sought for and the maximum % fall in
FEV1 from 3 to 7 h after the allergen challenge was evaluated as a measurement of magnitude of the LAR.
High intraclass correlation coecients (RI) were found for both PD20FEV1 (RI = 078) and LAR (RI = 077) in
all subjects. PD20FEV1 allergen showed a high RI in the long-interval group (RI = 080), but a low RI in the short-
interval group (RI = 063). In contrast LAR showed a lower RI in the long-interval group (RI = 068) than in the
short-interval group (RI = 077). Moreover, the RI for PD20FEV1 was particularly low in subjects with a dual
pattern to the allergen challenge and a short interval between the two allergen challenges.
Our study confirmed that asthmatic responses induced by allergen challenge have a good reproducibility.
Moreover, we have demonstrated that the interval between two allergen challenges can determine a change in
reproducibility in asthmatic responses induced by allergen challenge.
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Inhalation of a specific allergen in sensitized asthmatics can
induce an early asthmatic response (EAR), developing
10–30 min after allergen challenge, and a late asthmatic
response (LAR), which occurs a few hours (usually 6–8 h)
after allergen inhalation (1). LAR resolves more slowly
than EAR, and mimics spontaneous asthma attacks (2).
Allergen-induced asthmatic responses, especially LAR, can
be used to investigate the pathophysiology of asthma (3,4)
and to determine bronchial sensitivity to a specific allergen
(1). Moreover, allergen challenge is a useful method of
evaluating the ecacy of new medications, in the treatment
of asthma (1,5).Received 14 June 1999 accepted in revised form 25 November 1999.
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results should be able to reproduce EAR and LAR. Several
studies have examined the reproducibility of responses to
allergen challenge (6–13). Generally, the good repeatability
of an early response was described either when incremental
doses of allergen were inhaled to a provocative and (6,7,11),
or when the magnitude of the EAR was compared with a
similar allergen dose in both tests (8,9,12,13). Some studies
evaluated positive the reproducibility of the magnitude of
the LAR (8,9). These data are necessary to calculate sample
sizes required to show significant attenuation of both early
and late responses, and to identify appropriate uses of
allergen challenge (9). However, the relationship of within-
subject variability of EAR and LAR to the interval between
the two challenges has not yet been published.
The aim of this study was to measure the reproducibility
of allergen-induced early and late asthmatic responses in a
large sample of asthmatic patients and to relate the
reproducibility of EAR and LAR to the time between the
two challenges.# 2000 HARCOURT PUBLISHERS LTD
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SUBJECTS
Fifty-three subjects (23 female and 30 male, mean age 25
+10 years [range 15, 54]) with mild asthma were selected.
All were examined in a stable phase of the disease, and had
been free of respiratory infections and asthmatic exacerba-
tions during the previous 4 weeks. In a preliminary
evaluation, each subject had positive skin prick tests to
Dermatophagoides pteronyssinus and/or Dermatophagoides
farinae, Graminaceae or Parietaria (mean wheal diameter,
subtracted from negative control, 5 mm). Forty two
subjects were sensitized to house dust mite, 10 to
Graminaceae, one to Parietaria ocinalis. Baseline FEV1
was more than 65% of the predicted normal value in all
subjects on all study days. Forty-three subjects indicated
the presence of non specific bronchial hyperresponsiveness
to methacholine (PD20FEV1 5 1.0 mg).
STUDY DESIGN
Subjects attended for a baseline evaluation, including
personal history, a methacholine inhalation challenge test
and allergy skin prick tests. Subjects then underwent two
allergen inhalation challenge tests, not less than 2 and not
more than 26 weeks apart. Although some of them had
previously used sodium cromoglycate and inhaled gluco-
corticosteroids, in the month preceding the study all
patients were treated with inhaled salbutamol prn only.
Before each challenge, short-acting b2-agonists were with-
held for 12 h. Randomly, in a 1:2 ratio for short vs. long-
term reproducibility (in blocks of six subjects) 19 subjects
were assigned to the group with a short interval (14–35
days) and 34 to the group with a long interval (40–180 days)
between the two challenges. Each sought for the dose that
provoked a 20% decrease in FEV1 (PD20FEV1). Subjects
whose asthma or respiratory infections had exacerbated or
who required steroid treatment during the interval between
the two allergen challenges were excluded from the study.
Patients sensitive to Graminaceae and/or Parietaria were
studied out of the pollen season. This study was approved
by the local ethics committee.
SPECIFIC BRONCHIAL PROVOCATIVE
TEST WITH ALLERGEN (sBPT)
sBPT was performed with allergens standardized to
biologic units (BU). Allergen extract solution was delivered
by a DeVilbiss 646 jet nebulizer (DeVilbiss Health Care,
Somerset, PA, U.S.A.) using a procedure previously
described (14). Lyophilized allergen extract (NeoAbello`,
Milano, Italy) was dissolved in saline in order to obtain two
working solutions with dierent concentrations (1 and 10
BU/ml). The nebulizer was filled with 3 ml of diluent
(phenol 0.4% in saline) or allergen solution, and connected
to a dosimeter (Passerini, Pontedera, Italy) driven by
compressed air and activated as patients inhaled. With
the nebulizer vent closed, a 20 psi inlet pressure and 1 seclong nebulization, the output was 10 +1 ml, measured by
weighing the nebulizer before and after one discharge. The
aerodynamic mass median diameter of the aerosol gener-
ated was 12 mm (geometric standard deviation, 29),
measured with a cascade impactor. The output of the
nebulizer was regularly checked every 3 months. Each
subject wore a nose clip and was instructed to breath via a
mouthpiece from functional residual capacity. The nebuli-
zer was filled with 3 ml of allergen solution or diluent
control filtered through a 02 mm millipore filter. After
baseline evaluation, the patient inhaled three pus of
diluent, followed at 10 min intervals by increasing doses of
allergen to obtain the following cumulative logarithmic
doses, 0025, 005, 01, 02, 04, 08, 16, and 32 BU. FEV1
was measured 10 min after the end of each allergen dose by
means of a water sealed bell spirometer connected to an
Olivetti computer (Biomedin, Padova, Italy). The inhala-
tions were continued until FEV1 fell more than 20% below
the post-diluent value or until the last dose of allergen had
been administered, and the total dose (TD) of allergen
delivered was computed. FEV1 was then measured at 20, 30
and 60 min, and then hourly for 7 h. A fall in FEV1 greater
than 20% between 10 and 60 min, and between the third
and the seventh hour after the challenge was considered to
be an early asthmatic response (EAR) and a late asthmatic
response (LAR), respectively.
The dose of allergen causing a 20% fall in FEV1 from a
post-diluent value (PD20FEV1 allergen) was derived from
the following formula:
PD20FEV1 ÿ anti log
 
logpreTD
 logTD ÿ logpreTD  ÿ20ÿFEV1%preTDFEV1%TD ÿFEV1%preTD
 !
;
where: TD = threshold dose; preTD = previous dose to
threshold dose; DFEV1%TD =% fall of FEV1 with respect
to baseline at TD; DFEV1%preTD = % fall of FEV1 with
respect to preTD; antilog = anti-logarithm.
Subjects were included in the study if a decrease in FEV1
greater than 20% was observed during the early phase of
the first challenge.
STATISTICAL ANALYSIS
Baseline FEV1 was expressed as a percent of the predicted
value. Allergen-induced EAR was calculated as the max-
imal percent decrease in FEV1 from baseline within the first
hour after allergen, while LAR was evaluated as the
maximal percent decrease in FEV1 between 3 and 7 h after
allergen. These values were expressed as means and SE.
Logarithmic transformation was used to compare allergen
PD20FEV1. T test to compare FEV1, FEV1 percentage falls
and logPD20FEV1 was used. A level of probability lower
than 5% was considered significant. Reproducibility of
PD20FEV1 and LAR after allergen inhalation was plotted
according to the method proposed by Bland and Altman
(15). Intraclass correlation coecient was calculated by
EARLY AND LATE RESPONSES TO ALLERGEN CHALLENGE 443two-way ANOVA (16). Graphics of predicting sample sizes
were constructed by published power analysis (17).
Results
Fifty-eight subjects performed the first sBPT, of whom 53
also completed the second sBPT.
There was no significant dierence between the first and
second allergen challenge as regards baseline FEV1,
PD20FEV1 allergen, and DFEV1% during LAR, while
DFEV1% during EAR was significantly greater in second
test (DFEV1%, mean + SE, 7336 + 13 vs. 7370 14 in
the first and second test respectively, P5005) (Table 1).
In all subjects, the reproducibility of PD20FEV1 allergen
calculated in the first allergen challenge (BU, geometric
mean, 0.174) compared well with that of the second one
(0162 BU) (RI=078) (Fig. 1). No significant reproduci-
bility in DFEV1% during EAR between the two tests was
found (RI=016).
Forty-one subjects had a LAR after the first allergen
challenge (DFEV1%, mean + SE: 7284% +23), and 45
had a LAR after the second allergen challenge (7278% 
21). The magnitude of the FEV1 decrease during the LAR
was reproducible (RI = 077) (Fig. 1).
The patients were randomly grouped into a short-interval
group of 19 subjects, who performed the second allergen
challenge 14–35 days after the first allergen challenge (days,
mean: 197, and a long-interval group of 34 subjects the
second test 1–5 months after the first allergen challenge
(days, mean: 834. The two groups were comparable for
age, sex distribution, baseline FEV1, but there was a greater
reactivity to methacholine in the short-interval group in
comparison with the long-interval group (mg, GM: 0.080 vs
0283, P5005). There was no dierence between the two
groups as regards PD20FEV1 allergen, DFEV1% during
EAR and LAR (Table 2).
The PD20FEV1 allergen was highly reproducible in the
long interval group (BU, geometric mean, 0147 after the
first allergen challenge and 0152 after the second, RI =
080), while the intraclass correlation coecient was lower
in the short interval group (0229 after the first allergen
challenge and 0191 after the second, RI = 063). In
contrast, the magnitude of LAR showed a high RI in the
short interval group (FEV1%, mean + SE: 7243% + 33
after the first allergen challenge and 7259% + 34 afterTABLE 1. Characteristics of subjects at baseline evaluation and c
FEV1 baseline (% of predicted, mean + SEM)
PD20FEV1 allergen. (BU, GM and range)
EAR (DFEV1%, mean + SEM)
LAR (DFEV1%, mean +SEM)
*=P5005 vs. second allergen challenge.
BU=Biologic units; GM=geometric mean.the second RI = 077) but it was lower in the long interval
group (7303%+ 30 after the first allergen challenge and
7289%+ 27 after the second, RI = 068) (Figs 2 and 3).
In an individual analysis, 12 out of 19 patients in the short
interval group had a LAR in the first sBPT and 13 in the
second. On the other hand, 24 out of 34 subjects the long
interval group had a LAR in the first sBPT and 23 in the
second.
Moreover, PD20FEV1 allergen in subjects with EAR
alone separated from subjects with the dual response
(EARLAR), had a high intraclass correlation coecient
in 28 patients with the dual pattern and a long-interval
between the two tests (RI = 079), This result was also
evident in the two subgroups of subjects with the EAR
pattern (six in the short-interval group, RI = 077; six in the
long-interval group, RI = 092), while 13 patients with the
dual pattern and a short-interval between the two allergen
challenges had a low intraclass correlation coecient (RI =
055).
The required sample sizes needed to show a statistically
significant attenuation of an expected magnitude in the
asthmatic responses to allergen at a given power level are
illustrated in Fig. 4. Thus, if a drug was expected to produce
a 50% attenuation of the LAR, then less than 10 subjects
would be needed to show significance at a power level of
080 in a crossover study. If we consider PD20FEV1, then 14
subjects are needed to show a change of one doubling dose
at a power level of 080.
Discussion
Our study has demonstrated that the time between two
allergen challenges in sensitized subjects can influence the
repeatability of asthmatic responses. Moreover, our results
confirm the good reproducibility of asthmatic responses to
allergen in a large group of asthmatics, thus producing
further evidence for use of small samples in laboratory
studies.
Both asthmatic responses can be influenced by technical
and non-technical factors related to the procedure. Tech-
nical factors include the characteristics of the allergen
extracts, methods of aerosol generation, use of an appro-
priate dosimeter, and measurements of response (18). Of
the non technical factors, including subject characteristics
(19), many medications can, at least partially, inhibitomparing the first and second allergen challenges
1st allergen
challenge
2nd allergen
challenge
976 + 17 977 + 18
0174 [001, 284] 0162 [001, 302]
7336 + 13 * 7370 + 14
7284 + 23 7278 + 21
FIG 1. Upper panel. Repeatability of the PD20FEV1 allergen after two allergen challenges performed on two dierent days in
53 mild asthmatic adults. Lower panel. Repeatability of the magnitude of late asthmatic response (LAR) after two allergen
challenges performed on two dierent days in 53 mild asthmatic adults.
TABLE 2. Comparison between the first and second allergen challenges in the short and ‘long-interval’ groups of asthmatics
Short-interval group Long-interval group
no. 19 34
Time interval (days, mean and range) 197 [15, 30]* 834 [45, 150]
Age (yr, mean + SD) 237+83 259+ 106
Sex (M/F) 11/8 19/15
PD20FEV1 methacholine
(mg, GM and range)
0080 [0001, 1391]* 0283 [0283 [029, 40]
1st allergen
challenge
2nd allergen
challenge
1st allergn
challenge
2nd allergen
challenge
FEV1 baseline. (% of pred., mean + SEM) 1021 + 31 1000 + 32 953 + 20 965 + 23
PD20FEV1 Allergen (BU, GM and range) 023 [002, 148] 019 [001, 108] 015 [001, 284] 015 [001, 302]
EAR (DFEV1%, mean + SEM) 7338 + 1+8 7335 + 17* 7334 + 18 7389 + 19
LAR (DFEV1%, mean + SEM) 7243 + 3+3 7259 + 34 7308 +30 7289 +7
*=P50.05 vs. long-interval group.
BU = biologic Units; GM=geometric mean.
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FIG. 2. Upper panel. Repeatability of the PD20FEV1
allergen after two allergen challenges performed on two
dierent days at interval of lesser than 35 days in 19 mild
asthmatic adults. Lower panel: Repeatability of the
magnitude of the late asthmatic response (LAR) after two
allergen challenges performed on two dierent days at
intervals of less than 35 days in 19 mild asthmatic adults.
EARLY AND LATE RESPONSES TO ALLERGEN CHALLENGE 445asthmatic responses to allergen (20), while recent allergen
exposure (21) and previous respiratory infections (22,23)
may induce an increase of airway inflammation and a
change in allergen sensitivity and in the pattern of response.
Few studies examined the reproducibility of an early
response to allergen challenge, expressed as a provocative
dose (6,7,11). There is some discrepancy in the results.
Kopferschmitt-Kubler and co-workers (6) investigated the
reproducibility of the early asthmatic response to house
dust mite in 14 asthmatics and found a high correlation
coecient for PD20FEV1 after repeating the allergen
challenge after an interval of 2-weeks. However, the
intraclass correlation coecient calculated by the same
data was low (RI = 031). In our interpretation, this low
repeatability is due to the short interval between the two
tests. Rosenthal and co-workers (7) performed a 4 day
bronchial inhalation challenge to ragweed pollen plethy in
13 seasonal asthmatic patients, and airway conductance
was measured in the body pletismograph, calculating the
PD35sGaw. Investigators confirmed that the reproducibility
was satisfactory. But it is possible to calculate PD35sGaw, a
high RI between the 1st and 2nd day (RI = 081), as well as
between the 1st and the 3rd day (RI = 083), and asignificantly lower RI between the 1st and the 4th day (RI
= 056). This result can be explained by the short interval
between allergen challenge tests and consequently by the
cumulated influence of previous tests on subsequent tests.
On the other hand, Frølund and co-authors (11) studied the
reproducibility of EAR in 13 asthmatics sensitized to
various allergens within an interval of 14 days with 10-fold
increasing concentrations of allergen solutions. They found
that PC20FEV1 had a good reproducibility (CoV 85%; RI
= 099). It is possible that the subjects of that study had a
response pattern (e.g. early response alone) to the allergen
challenge but that the short interval between the two tests
did not influence the PC20FEV1. We have demonstrated in
our study that the provocative dose of allergen is
significantly changed between two tests only in subjects
with a dual pattern.
In our study, a low reproducibility of the magnitude of
the EAR, expressed as DFEV1%, was found, similar to
other studies (9,24). This is because of the design of the
specific bronchial test, performed to obtain an immediate
DFEV1% in a narrow range. Consequently, this narrow
range of an early fall of FEV1 prevents a high intraclass
coecient for that variable. In other studies, investigators
found good reproducibility of the magnitude of EAR
(8,12,13), but they probably had a greater range of
response, which improves the calculation of the intraclass
correlation coecient.
Only a few studies have examined the reproducibility of
LAR due to allergen challenge. Cockcroft and co-workers
found it to be rather low, but calculated it as a coecient of
variation (10). Two studies evaluated the reproducibility of
LAR as an intraclass correlation coecient, with a high R1
value (8,9). Our study confirms this good repeatability of
LAR, but that the repeatability of LAR is less accurate
when the interval between the two tests is longer than 30
days.
In this study, we have demonstrated that the duration of
time between two allergen challenges in sensitized subjects
influences the repeatability of measurements of EAR and
LAR.
EAR expressed as PD20FEV1, has a good reproducibility
if the interval between the two challenges is longer than 30
days. If the interval is shorter than 30 days, the second
PD20FEV1 is less satisfactory than the first. More
accurately, we have demonstrated that the shortness of
the interval has an eect on the repeatability of the
PD20FEV1 allergen if a LAR is present, while the
PD20FEV1 allergen is not influenced by the duration of
the time interval in subjects with EAR alone. The
functional eects of a LAR, as symptoms and/or as non
specific bronchial hypereactivity, can persist for a long
period after an allergen challenge (2,25,26). Thus, we
suggest that, in studies in which a comparison between
PD20FEV1 allergen is required, sensitized subjects with an
isolated EAR to allergen can be included following allergen
challenges. In addition, if the interval between challenges is
short, deterioration of the immediate response to allergen in
the second test should be minimal. We have demonstrated
that LAR shows good reproducibility only when the
interval is short, while the repeatability of the magnitude
FIG 3. Upper panel. Repeatability of the PD20FEV1 allergen after two allergen challenges performed on two dierent days at
intervals greater than 35 days in 34 mild asthmatic adults. Lower panel. Repeatability of the magnitude of the late asthmatic
response (LAR) after two allergen challenges performed on two dierent days at intervals greater than 35 days in 34 mild
asthmatic adults.
FIG 4. Curves allowing estimation of sample sizes for given power and expected attenuation of PD20FEV1 allergen (right)
and maximal decrease in FEV1 during late asthmatic response (LAR) (left).
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EARLY AND LATE RESPONSES TO ALLERGEN CHALLENGE 447of LAR is less accurate when the interval is longer than 30
days. We argue that, with a longer interval, it is easier for
new conditions (e.g. exposure to allergen or also airway
infections) to alter the magnitude of the LAR, according to
experimental data (21–23). Consequently, when measuring
the eects of treatment on the LAR, subsequent allergen
challenges must be separated by intervals of less than 35
days.
The high reproducibility of the EAR and LAR measure-
ments after allergen challenge allows sample sizes to be used
in order to detect changes in asthmatic responses in
experimental conditions. These findings support the results
of studies in which significant eects of drugs, on both EAR
and LAR have been found with sample sizes of about 12
subjects.
In conclusion, our study shows that asthmatic responses
induced by allergen challenge are reproducible but that the
interval between two allergen challenges is crucial in order
to obtain a good reproducibility of EAR and LAR.
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